New CIBMTR Analysis: CD19 CAR T in Primary Mediastinal B-Cell Lymphoma - Yan Leyfman
@yleyfman.bsky.social
oncodaily.com/insight/yan-...
#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #CIBMTR #CART #IO #Lymphoma
@yleyfman.bsky.social
oncodaily.com/insight/yan-...
#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #CIBMTR #CART #IO #Lymphoma
Yan Leyfman: New CIBMTR Analysis - CD19 CAR T in Primary Mediastinal B-Cell Lymphoma - OncoDaily
Yan Leyfman: New CIBMTR Analysis - CD19 CAR T in Primary Mediastinal B-Cell Lymphoma / Adriana Malone, Alberto Mussetti, Alex F. Herrera, Anna Sureda,
oncodaily.com
August 16, 2025 at 8:04 PM
New CIBMTR Analysis: CD19 CAR T in Primary Mediastinal B-Cell Lymphoma - Yan Leyfman
@yleyfman.bsky.social
oncodaily.com/insight/yan-...
#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #CIBMTR #CART #IO #Lymphoma
@yleyfman.bsky.social
oncodaily.com/insight/yan-...
#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #CIBMTR #CART #IO #Lymphoma
📢 #Tandem27 registration is open!
Join ASTCT and CIBMTR for the latest research, emerging therapies, and advances in transplantation and cellular therapy.
📍 Orlando, FL | 📅 Feb. 17-20, 2027
Register: www.tandemmeetings.com/Registration...
Join ASTCT and CIBMTR for the latest research, emerging therapies, and advances in transplantation and cellular therapy.
📍 Orlando, FL | 📅 Feb. 17-20, 2027
Register: www.tandemmeetings.com/Registration...
October 7, 2026 at 6:39 PM
📢 #Tandem27 registration is open!
Join ASTCT and CIBMTR for the latest research, emerging therapies, and advances in transplantation and cellular therapy.
📍 Orlando, FL | 📅 Feb. 17-20, 2027
Register: www.tandemmeetings.com/Registration...
Join ASTCT and CIBMTR for the latest research, emerging therapies, and advances in transplantation and cellular therapy.
📍 Orlando, FL | 📅 Feb. 17-20, 2027
Register: www.tandemmeetings.com/Registration...
Just out in @astct.bsky.social: Updated allogeneic stem cell donor selection guidelines from the CIBMTR/NMDP. Kudos to @mskcancercenter.bsky.social's Brian Shaffer and team! #stemcelltransplant #Cancer www.sciencedirect.com/science/arti...
July 10, 2025 at 8:07 PM
Just out in @astct.bsky.social: Updated allogeneic stem cell donor selection guidelines from the CIBMTR/NMDP. Kudos to @mskcancercenter.bsky.social's Brian Shaffer and team! #stemcelltransplant #Cancer www.sciencedirect.com/science/arti...
Fred Hutch’s latest findings on transplantation, cell therapies, immunology and more will be featured at the 2025 Tandem Meetings of @astct.bsky.social and @cibmtr.bsky.social. bit.ly/4jPNQXE #Tandem25
ASTCT and CIBMTR 2025
Fred Hutch scientists are presenting new research findings at the Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR on February 12-15, 2025. The ASTCT and CIBMTR tandem meetings features...
bit.ly
February 10, 2025 at 10:05 PM
Fred Hutch’s latest findings on transplantation, cell therapies, immunology and more will be featured at the 2025 Tandem Meetings of @astct.bsky.social and @cibmtr.bsky.social. bit.ly/4jPNQXE #Tandem25
NOW AVAILABLE: 2024 CIBMTR Summary Slides. These slides provide an annual report on data submitted by US centers to CIBMTR, detailing practices and general survival outcomes following cellular therapies. Learn more: cibmtr.org/CIBMTR/Resou...
April 28, 2025 at 7:33 PM
NOW AVAILABLE: 2024 CIBMTR Summary Slides. These slides provide an annual report on data submitted by US centers to CIBMTR, detailing practices and general survival outcomes following cellular therapies. Learn more: cibmtr.org/CIBMTR/Resou...
New from #StemCellEvidence:
Current Activity Trends and Outcomes in Hematopoietic Cell Transplantation and Cellular Therapy - A report from the CIBMTR
by Spellman et al.
www.stemcellevidence.com/alerts/artic...
Current Activity Trends and Outcomes in Hematopoietic Cell Transplantation and Cellular Therapy - A report from the CIBMTR
by Spellman et al.
www.stemcellevidence.com/alerts/artic...
July 11, 2025 at 8:23 AM
New from #StemCellEvidence:
Current Activity Trends and Outcomes in Hematopoietic Cell Transplantation and Cellular Therapy - A report from the CIBMTR
by Spellman et al.
www.stemcellevidence.com/alerts/artic...
Current Activity Trends and Outcomes in Hematopoietic Cell Transplantation and Cellular Therapy - A report from the CIBMTR
by Spellman et al.
www.stemcellevidence.com/alerts/artic...
Ready to kick off @astct.bsky.social @cibmtr.bsky.social #tandem25 with ASTCT President Corey Cutler & CIBMTR scientific co-directors Bronwen Shaw and Jeff Auletta - taking a moment to recognize the importance of NIH support for our work & our NIH colleagues who are unable to join the meeting.
February 12, 2025 at 6:26 PM
Ready to kick off @astct.bsky.social @cibmtr.bsky.social #tandem25 with ASTCT President Corey Cutler & CIBMTR scientific co-directors Bronwen Shaw and Jeff Auletta - taking a moment to recognize the importance of NIH support for our work & our NIH colleagues who are unable to join the meeting.
It's not too late to add the NMDP/CIBMTR community to your #Tandem2026 agenda! Check out these notable presentations from the ACCESS Trial ⬇️
February 4, 2026 at 5:57 PM
It's not too late to add the NMDP/CIBMTR community to your #Tandem2026 agenda! Check out these notable presentations from the ACCESS Trial ⬇️
#Tandem25 I'll be talking today (10.30am Ballrm B, 4th flr) about Pre-MEASURE use of CIBMTR Clinical Data & Biospecimens. Current issue nature.com/BMT focuses on this, and is dedicated to co-author Dr. Kristin Page www.nature.com/articles/s41...
Pls consider donating www.gofundme.com/f/dwkhq-supp...
Pls consider donating www.gofundme.com/f/dwkhq-supp...
nature.com
February 12, 2025 at 7:29 PM
#Tandem25 I'll be talking today (10.30am Ballrm B, 4th flr) about Pre-MEASURE use of CIBMTR Clinical Data & Biospecimens. Current issue nature.com/BMT focuses on this, and is dedicated to co-author Dr. Kristin Page www.nature.com/articles/s41...
Pls consider donating www.gofundme.com/f/dwkhq-supp...
Pls consider donating www.gofundme.com/f/dwkhq-supp...
It gives us great pleasure to announce that Amy Moskop, MD, MS, has been confirmed as the new co-Principal Investigator (PI) on U24-CA076518: A Data Resource for Blood and Marrow Transplants and Adoptive Cellular Therapy Research. Read more: cibmtr.org/CIBMTR/About...
Amy Moskop, New ACT Lead for CIBMTR
cibmtr.org
October 15, 2025 at 7:05 PM
It gives us great pleasure to announce that Amy Moskop, MD, MS, has been confirmed as the new co-Principal Investigator (PI) on U24-CA076518: A Data Resource for Blood and Marrow Transplants and Adoptive Cellular Therapy Research. Read more: cibmtr.org/CIBMTR/About...
Liso-cel demonstrated safety and efficacy outcomes that were comparable to those in the pivotal TRANSFORM and PILOT trials in patients with relapsed/refractory large B-cell lymphoma. #lymsm #ash24 #CARTcells
www.onclive.com/view/liso-ce...
www.onclive.com/view/liso-ce...
Liso-Cel Shows Broad Spectrum Activity in CIBMTR Cohort of Relapsed/Refractory LBCL
Liso-cel demonstrated safety and efficacy outcomes that were comparable to those in the pivotal TRANSFORM and PILOT trials in patients with relapsed/refractory large B-cell lymphoma.
www.onclive.com
December 9, 2024 at 3:58 AM
Liso-cel demonstrated safety and efficacy outcomes that were comparable to those in the pivotal TRANSFORM and PILOT trials in patients with relapsed/refractory large B-cell lymphoma. #lymsm #ash24 #CARTcells
www.onclive.com/view/liso-ce...
www.onclive.com/view/liso-ce...
February 13, 2025 at 3:15 AM
Just Published in Transplantation and Cellular Therapy Journal: Allogeneic Hematopoietic Cell Donor Selection: Contemporary Guidelines from the NMDP/CIBMTR. Read more: www.sciencedirect.com/science/arti...
Allogeneic Hematopoietic Cell Donor Selection: Contemporary Guidelines from the NMDP/CIBMTR
Allogeneic hematopoietic cell transplantation (HCT) remains a curative therapy for many patients with hematologic malignancies, bone marrow failure sy…
www.sciencedirect.com
July 7, 2025 at 9:07 PM
Just Published in Transplantation and Cellular Therapy Journal: Allogeneic Hematopoietic Cell Donor Selection: Contemporary Guidelines from the NMDP/CIBMTR. Read more: www.sciencedirect.com/science/arti...
New from #StemCellEvidence:
Outcomes of allogeneic HCT in Hodgkin lymphoma in the era of checkpoint inhibitors: a joint CIBMTR and EBMT analysis
by Perales et al.
www.stemcellevidence.com/articles/406...
#MedSky
Outcomes of allogeneic HCT in Hodgkin lymphoma in the era of checkpoint inhibitors: a joint CIBMTR and EBMT analysis
by Perales et al.
www.stemcellevidence.com/articles/406...
#MedSky
September 11, 2025 at 1:04 PM
New from #StemCellEvidence:
Outcomes of allogeneic HCT in Hodgkin lymphoma in the era of checkpoint inhibitors: a joint CIBMTR and EBMT analysis
by Perales et al.
www.stemcellevidence.com/articles/406...
#MedSky
Outcomes of allogeneic HCT in Hodgkin lymphoma in the era of checkpoint inhibitors: a joint CIBMTR and EBMT analysis
by Perales et al.
www.stemcellevidence.com/articles/406...
#MedSky
🩺🩸Only 60% of South American centers use the international patient transfer tool ( #CIBMTR ), essential for post–stem cell transplantation follow-up. Low adherence may compromise data quality and clinical surveillance.
doi.org/10.46765/267...
#stemcelltransplantation #oncology #celltherapy
doi.org/10.46765/267...
#stemcelltransplantation #oncology #celltherapy
October 2, 2025 at 3:12 PM
🩺🩸Only 60% of South American centers use the international patient transfer tool ( #CIBMTR ), essential for post–stem cell transplantation follow-up. Low adherence may compromise data quality and clinical surveillance.
doi.org/10.46765/267...
#stemcelltransplantation #oncology #celltherapy
doi.org/10.46765/267...
#stemcelltransplantation #oncology #celltherapy
NOW AVAILABLE: 2025 CIBMTR Summary Slides. These slides provide an annual report on data submitted by US centers to CIBMTR, detailing practices and general survival outcomes following cellular therapies. Learn more: cibmtr.org/CIBMTR/Resou...
June 17, 2026 at 9:47 PM
NOW AVAILABLE: 2025 CIBMTR Summary Slides. These slides provide an annual report on data submitted by US centers to CIBMTR, detailing practices and general survival outcomes following cellular therapies. Learn more: cibmtr.org/CIBMTR/Resou...
Dr. Miguel-Angel Perales (@drmiguelperales.bsky.social) concludes the CIBMTR Concurrent Session with “Use of CIBMTR One Year Survival Calculator for Retrospective Analysis” at #Tandem26 this morning!
February 4, 2026 at 6:23 PM
Dr. Miguel-Angel Perales (@drmiguelperales.bsky.social) concludes the CIBMTR Concurrent Session with “Use of CIBMTR One Year Survival Calculator for Retrospective Analysis” at #Tandem26 this morning!
CIBMTR and the MCW Division of Hematology and Oncology invite applications for a faculty position as a CIBMTR Scientific Director. Learn more about and apply for this important position: careers.peopleclick.com/careerscp/cl...
October 7, 2025 at 7:55 PM
CIBMTR and the MCW Division of Hematology and Oncology invite applications for a faculty position as a CIBMTR Scientific Director. Learn more about and apply for this important position: careers.peopleclick.com/careerscp/cl...
#StemCellEvidence link to:
PTCy-Based versus ATG-Based GVHD Prophylaxis in Mismatched Unrelated Donor HCT: A Secondary Analysis of CIBMTR Data
by Rodriguez-Rodriguez et al.
www.stemcellevidence.com/alerts/artic...
#MedSky
PTCy-Based versus ATG-Based GVHD Prophylaxis in Mismatched Unrelated Donor HCT: A Secondary Analysis of CIBMTR Data
by Rodriguez-Rodriguez et al.
www.stemcellevidence.com/alerts/artic...
#MedSky
PTCy-Based versus ATG-Based GVHD Prophylaxis in Mismatched Unrelated Donor HCT: A Secondary Analysis of CIBMTR Data
The optimal graft-versus-host disease (GVHD) prophylaxis strategy for 7/8 human leukocyte antigen (HLA)-mismatched unrelated donor (MMUD) hematopoietic cell transplantation (HCT) has not been establis...
www.stemcellevidence.com
July 10, 2026 at 8:49 AM
#StemCellEvidence link to:
PTCy-Based versus ATG-Based GVHD Prophylaxis in Mismatched Unrelated Donor HCT: A Secondary Analysis of CIBMTR Data
by Rodriguez-Rodriguez et al.
www.stemcellevidence.com/alerts/artic...
#MedSky
PTCy-Based versus ATG-Based GVHD Prophylaxis in Mismatched Unrelated Donor HCT: A Secondary Analysis of CIBMTR Data
by Rodriguez-Rodriguez et al.
www.stemcellevidence.com/alerts/artic...
#MedSky
We’re thrilled that both our adult and pediatric stem cell/bone marrow transplant programs earned the highest possible +1 score in the 2025 CIBMTR Survival Report — exceeding expected 1-year survival nationwide. Thank you to our dedicated team and partners for advancing patient care every day.
Dana-Farber Cancer Institute and Dana-Farber/Boston Children’s Cancer and Blood Disorders Center recognized for exceptional outcomes in donor stem cell transplants | Dana-Farber Cancer Institute
Dana-Farber Cancer Institute’s adult stem cell transplant program and Dana-Farber/Boston Children’s Cancer and Blood Disorders Center’s pediatric stem cell transplant program have once again received exceptional ratings from the Center for International Blood & Marrow Transplant Research (CIBMTR), earning a +1 performance score, the highest possible designation, on their annual center-specific survival reports. The +1 scores reflect that both programs outperformed the expected one-year survival rate for allogeneic (donor) stem cell transplants in the United States.
bit.ly
December 22, 2025 at 9:39 PM
We’re thrilled that both our adult and pediatric stem cell/bone marrow transplant programs earned the highest possible +1 score in the 2025 CIBMTR Survival Report — exceeding expected 1-year survival nationwide. Thank you to our dedicated team and partners for advancing patient care every day.
よ～～～しCIBMTR振り返り書き終わった～～
March 16, 2025 at 4:39 AM
よ～～～しCIBMTR振り返り書き終わった～～
NEW: CIBMTR Research
Outcomes of HCT in patients with plasmablastic lymphoma
Read more:
🔗 pubmed.ncbi.nlm.nih.gov/42173253/
Outcomes of HCT in patients with plasmablastic lymphoma
Read more:
🔗 pubmed.ncbi.nlm.nih.gov/42173253/
June 24, 2026 at 6:00 PM
NEW: CIBMTR Research
Outcomes of HCT in patients with plasmablastic lymphoma
Read more:
🔗 pubmed.ncbi.nlm.nih.gov/42173253/
Outcomes of HCT in patients with plasmablastic lymphoma
Read more:
🔗 pubmed.ncbi.nlm.nih.gov/42173253/